750 related articles for article (PubMed ID: 17561264)
21. FTY720 on the way from the base camp to the summit of the mountain: relevance for remyelination.
Kipp M; Amor S
Mult Scler; 2012 Mar; 18(3):258-63. PubMed ID: 22383435
[TBL] [Abstract][Full Text] [Related]
22. New players on the center stage: sphingosine 1-phosphate and its receptors as drug targets.
Huwiler A; Pfeilschifter J
Biochem Pharmacol; 2008 May; 75(10):1893-900. PubMed ID: 18321471
[TBL] [Abstract][Full Text] [Related]
23. The immunosuppressant FTY720 inhibits tumor angiogenesis via the sphingosine 1-phosphate receptor 1.
Schmid G; Guba M; Ischenko I; Papyan A; Joka M; Schrepfer S; Bruns CJ; Jauch KW; Heeschen C; Graeb C
J Cell Biochem; 2007 May; 101(1):259-70. PubMed ID: 17203465
[TBL] [Abstract][Full Text] [Related]
24. Sphingosine-1-phosphate stimulates the functional capacity of progenitor cells by activation of the CXCR4-dependent signaling pathway via the S1P3 receptor.
Walter DH; Rochwalsky U; Reinhold J; Seeger F; Aicher A; Urbich C; Spyridopoulos I; Chun J; Brinkmann V; Keul P; Levkau B; Zeiher AM; Dimmeler S; Haendeler J
Arterioscler Thromb Vasc Biol; 2007 Feb; 27(2):275-82. PubMed ID: 17158356
[TBL] [Abstract][Full Text] [Related]
25. Attenuation of cell motility observed with high doses of sphingosine 1-phosphate or phosphorylated FTY720 involves RGS2 through its interactions with the receptor S1P.
Kohno T; Igarashi Y
Genes Cells; 2008 Jul; 13(7):747-57. PubMed ID: 18513330
[TBL] [Abstract][Full Text] [Related]
26. Role of sphingosine 1-phosphate receptor type 1 in lymphocyte egress from secondary lymphoid tissues and thymus.
Chiba K; Matsuyuki H; Maeda Y; Sugahara K
Cell Mol Immunol; 2006 Feb; 3(1):11-9. PubMed ID: 16549044
[TBL] [Abstract][Full Text] [Related]
27. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis.
Mehling M; Brinkmann V; Antel J; Bar-Or A; Goebels N; Vedrine C; Kristofic C; Kuhle J; Lindberg RL; Kappos L
Neurology; 2008 Oct; 71(16):1261-7. PubMed ID: 18852441
[TBL] [Abstract][Full Text] [Related]
28. FTY720 (fingolimod) for relapsing multiple sclerosis.
Horga A; Montalban X
Expert Rev Neurother; 2008 May; 8(5):699-714. PubMed ID: 18457527
[TBL] [Abstract][Full Text] [Related]
29. Sphingosine 1-phosphate receptor modulator fingolimod (FTY720) does not promote remyelination in vivo.
Hu Y; Lee X; Ji B; Guckian K; Apicco D; Pepinsky RB; Miller RH; Mi S
Mol Cell Neurosci; 2011 Sep; 48(1):72-81. PubMed ID: 21740973
[TBL] [Abstract][Full Text] [Related]
30. The role of sphingosine-1-phosphate receptor modulators in the prevention of transplant rejection and autoimmune diseases.
Japtok L; Kleuser B
Curr Opin Investig Drugs; 2009 Nov; 10(11):1183-94. PubMed ID: 19876786
[TBL] [Abstract][Full Text] [Related]
31. Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes.
Forrest M; Sun SY; Hajdu R; Bergstrom J; Card D; Doherty G; Hale J; Keohane C; Meyers C; Milligan J; Mills S; Nomura N; Rosen H; Rosenbach M; Shei GJ; Singer II; Tian M; West S; White V; Xie J; Proia RL; Mandala S
J Pharmacol Exp Ther; 2004 May; 309(2):758-68. PubMed ID: 14747617
[TBL] [Abstract][Full Text] [Related]
32. Relevance and potential of sphingosine-1-phosphate in vascular inflammatory disease.
van der Giet M; Tölle M; Kleuser B
Biol Chem; 2008 Nov; 389(11):1381-90. PubMed ID: 18925828
[TBL] [Abstract][Full Text] [Related]
33. Ascomycete derivative to MS therapeutic: S1P receptor modulator FTY720.
Hiestand PC; Rausch M; Meier DP; Foster CA
Prog Drug Res; 2008; 66():361, 363-81. PubMed ID: 18416311
[TBL] [Abstract][Full Text] [Related]
34. The S1P receptor modulator FTY720 prevents the development of experimental colitis in mice.
Deguchi Y; Andoh A; Yagi Y; Bamba S; Inatomi O; Tsujikawa T; Fujiyama Y
Oncol Rep; 2006 Oct; 16(4):699-703. PubMed ID: 16969482
[TBL] [Abstract][Full Text] [Related]
35. Pulmonary and vascular pharmacology of sphingosine 1-phosphate.
Brinkmann V; Baumruker T
Curr Opin Pharmacol; 2006 Jun; 6(3):244-50. PubMed ID: 16563863
[TBL] [Abstract][Full Text] [Related]
36. Structural and functional characteristics of S1P receptors.
Sanchez T; Hla T
J Cell Biochem; 2004 Aug; 92(5):913-22. PubMed ID: 15258915
[TBL] [Abstract][Full Text] [Related]
37. Tipping the gatekeeper: S1P regulation of endothelial barrier function.
Rosen H; Sanna MG; Cahalan SM; Gonzalez-Cabrera PJ
Trends Immunol; 2007 Mar; 28(3):102-7. PubMed ID: 17276731
[TBL] [Abstract][Full Text] [Related]
38. FTY720 (fingolimod) in renal transplantation.
Budde K; Schütz M; Glander P; Peters H; Waiser J; Liefeldt L; Neumayer HH; Böhler T
Clin Transplant; 2006; 20 Suppl 17():17-24. PubMed ID: 17100697
[TBL] [Abstract][Full Text] [Related]
39. Accumulation of fingolimod (FTY720) in lymphoid tissues contributes to prolonged efficacy.
Sensken SC; Bode C; Gräler MH
J Pharmacol Exp Ther; 2009 Mar; 328(3):963-9. PubMed ID: 19074680
[TBL] [Abstract][Full Text] [Related]
40. Sphingosine 1-phosphate receptor agonism impairs skin dendritic cell migration and homing to secondary lymphoid tissue: association with prolonged allograft survival.
Lan YY; Tokita D; Wang Z; Wang HC; Zhan J; Brinkmann V; Thomson AW
Transpl Immunol; 2008 Nov; 20(1-2):88-94. PubMed ID: 18694829
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
